![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NSDHL |
Gene summary for NSDHL |
![]() |
Gene information | Species | Human | Gene symbol | NSDHL | Gene ID | 50814 |
Gene name | NAD(P) dependent steroid dehydrogenase-like | |
Gene Alias | H105E3 | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q15738 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
50814 | NSDHL | LZE2T | Human | Esophagus | ESCC | 2.39e-02 | 3.07e-01 | 0.082 |
50814 | NSDHL | LZE4T | Human | Esophagus | ESCC | 6.31e-06 | 2.53e-01 | 0.0811 |
50814 | NSDHL | LZE7T | Human | Esophagus | ESCC | 7.44e-08 | 5.64e-01 | 0.0667 |
50814 | NSDHL | LZE24T | Human | Esophagus | ESCC | 3.59e-10 | 2.93e-01 | 0.0596 |
50814 | NSDHL | LZE6T | Human | Esophagus | ESCC | 3.07e-02 | 2.26e-01 | 0.0845 |
50814 | NSDHL | P1T-E | Human | Esophagus | ESCC | 3.41e-09 | 3.92e-01 | 0.0875 |
50814 | NSDHL | P2T-E | Human | Esophagus | ESCC | 2.61e-16 | 3.19e-01 | 0.1177 |
50814 | NSDHL | P4T-E | Human | Esophagus | ESCC | 1.41e-16 | 4.79e-01 | 0.1323 |
50814 | NSDHL | P5T-E | Human | Esophagus | ESCC | 2.71e-16 | 3.46e-01 | 0.1327 |
50814 | NSDHL | P8T-E | Human | Esophagus | ESCC | 1.19e-11 | 2.06e-01 | 0.0889 |
50814 | NSDHL | P9T-E | Human | Esophagus | ESCC | 5.56e-15 | 3.58e-01 | 0.1131 |
50814 | NSDHL | P10T-E | Human | Esophagus | ESCC | 5.61e-26 | 6.96e-01 | 0.116 |
50814 | NSDHL | P11T-E | Human | Esophagus | ESCC | 3.51e-03 | 2.11e-01 | 0.1426 |
50814 | NSDHL | P12T-E | Human | Esophagus | ESCC | 3.68e-19 | 3.49e-01 | 0.1122 |
50814 | NSDHL | P15T-E | Human | Esophagus | ESCC | 9.75e-09 | 2.76e-01 | 0.1149 |
50814 | NSDHL | P16T-E | Human | Esophagus | ESCC | 2.19e-11 | 8.46e-02 | 0.1153 |
50814 | NSDHL | P19T-E | Human | Esophagus | ESCC | 1.02e-08 | 6.90e-01 | 0.1662 |
50814 | NSDHL | P20T-E | Human | Esophagus | ESCC | 6.09e-12 | 3.35e-01 | 0.1124 |
50814 | NSDHL | P21T-E | Human | Esophagus | ESCC | 7.74e-36 | 6.43e-01 | 0.1617 |
50814 | NSDHL | P22T-E | Human | Esophagus | ESCC | 9.98e-60 | 1.08e+00 | 0.1236 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00987732 | Skin | cSCC | skin epidermis development | 38/4864 | 85/18723 | 1.41e-04 | 1.27e-03 | 38 |
GO:006071122 | Skin | cSCC | labyrinthine layer development | 23/4864 | 44/18723 | 1.74e-04 | 1.49e-03 | 23 |
GO:00019422 | Skin | cSCC | hair follicle development | 36/4864 | 81/18723 | 2.40e-04 | 1.96e-03 | 36 |
GO:004230321 | Skin | cSCC | molting cycle | 44/4864 | 107/18723 | 4.41e-04 | 3.39e-03 | 44 |
GO:004263321 | Skin | cSCC | hair cycle | 44/4864 | 107/18723 | 4.41e-04 | 3.39e-03 | 44 |
GO:002240421 | Skin | cSCC | molting cycle process | 36/4864 | 84/18723 | 5.64e-04 | 4.12e-03 | 36 |
GO:002240521 | Skin | cSCC | hair cycle process | 36/4864 | 84/18723 | 5.64e-04 | 4.12e-03 | 36 |
GO:00066954 | Skin | cSCC | cholesterol biosynthetic process | 25/4864 | 57/18723 | 2.55e-03 | 1.45e-02 | 25 |
GO:19026534 | Skin | cSCC | secondary alcohol biosynthetic process | 25/4864 | 57/18723 | 2.55e-03 | 1.45e-02 | 25 |
GO:00161264 | Skin | cSCC | sterol biosynthetic process | 27/4864 | 64/18723 | 3.44e-03 | 1.86e-02 | 27 |
GO:19026525 | Skin | cSCC | secondary alcohol metabolic process | 53/4864 | 147/18723 | 4.33e-03 | 2.27e-02 | 53 |
GO:00461654 | Skin | cSCC | alcohol biosynthetic process | 50/4864 | 140/18723 | 6.73e-03 | 3.27e-02 | 50 |
Page: 1 2 3 4 5 6 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa001005 | Esophagus | ESCC | Steroid biosynthesis | 18/4205 | 20/8465 | 1.78e-04 | 6.79e-04 | 3.48e-04 | 18 |
hsa0010012 | Esophagus | ESCC | Steroid biosynthesis | 18/4205 | 20/8465 | 1.78e-04 | 6.79e-04 | 3.48e-04 | 18 |
hsa00100 | Liver | Cirrhotic | Steroid biosynthesis | 12/2530 | 20/8465 | 4.92e-03 | 1.76e-02 | 1.09e-02 | 12 |
hsa001001 | Liver | Cirrhotic | Steroid biosynthesis | 12/2530 | 20/8465 | 4.92e-03 | 1.76e-02 | 1.09e-02 | 12 |
hsa001002 | Liver | HCC | Steroid biosynthesis | 15/4020 | 20/8465 | 1.17e-02 | 2.97e-02 | 1.65e-02 | 15 |
hsa001003 | Liver | HCC | Steroid biosynthesis | 15/4020 | 20/8465 | 1.17e-02 | 2.97e-02 | 1.65e-02 | 15 |
hsa001004 | Oral cavity | OSCC | Steroid biosynthesis | 15/3704 | 20/8465 | 4.62e-03 | 1.13e-02 | 5.75e-03 | 15 |
hsa0010011 | Oral cavity | OSCC | Steroid biosynthesis | 15/3704 | 20/8465 | 4.62e-03 | 1.13e-02 | 5.75e-03 | 15 |
hsa0010021 | Oral cavity | LP | Steroid biosynthesis | 11/2418 | 20/8465 | 1.16e-02 | 3.91e-02 | 2.52e-02 | 11 |
hsa0010031 | Oral cavity | LP | Steroid biosynthesis | 11/2418 | 20/8465 | 1.16e-02 | 3.91e-02 | 2.52e-02 | 11 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NSDHL | SNV | Missense_Mutation | c.130N>A | p.Gly44Ser | p.G44S | Q15738 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NSDHL | SNV | Missense_Mutation | rs782205394 | c.29N>A | p.Arg10Lys | p.R10K | Q15738 | protein_coding | tolerated_low_confidence(0.82) | benign(0) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NSDHL | SNV | Missense_Mutation | rs781879080 | c.263N>A | p.Arg88Gln | p.R88Q | Q15738 | protein_coding | tolerated(0.43) | benign(0) | TCGA-OL-A5S0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | CR |
NSDHL | insertion | Frame_Shift_Ins | novel | c.826_827insATTTACAGCAGTTGCAAGCGTGCAGACAGGAATCA | p.Trp276TyrfsTer20 | p.W276Yfs*20 | Q15738 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
NSDHL | insertion | Nonsense_Mutation | novel | c.365_366insAAT | p.Tyr122delinsTer | p.Y122delins* | Q15738 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
NSDHL | insertion | In_Frame_Ins | novel | c.367_368insAACAGACCTGTTTTAAAAATCCCTTTCAGG | p.Ile123delinsLysGlnThrCysPheLysAsnProPheGlnVal | p.I123delinsKQTCFKNPFQV | Q15738 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
NSDHL | insertion | Frame_Shift_Ins | novel | c.307dupC | p.His103ProfsTer10 | p.H103Pfs*10 | Q15738 | protein_coding | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
NSDHL | SNV | Missense_Mutation | novel | c.274N>C | p.Tyr92His | p.Y92H | Q15738 | protein_coding | tolerated(0.14) | possibly_damaging(0.744) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NSDHL | SNV | Missense_Mutation | c.202N>C | p.Asp68His | p.D68H | Q15738 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-C5-A2LS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
NSDHL | SNV | Missense_Mutation | novel | c.616C>G | p.Pro206Ala | p.P206A | Q15738 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |